On April 19, 2017 Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, reported issuance of a U.S. patent for KO-947, its drug candidate targeting extracellular-signal-regulated kinases (ERK) (Press release, Kura Oncology, APR 19, 2017, View Source [SID1234518614]). The new patent, U.S. 9,624,228, entitled "Inhibitors of ERK and Methods of Use," covers KO-947 and structurally-related compounds as well as methods of using the compounds for the treatment of diseases including cancer. Schedule your 30 min Free 1stOncology Demo! "We believe KO-947 holds much promise as a potential therapeutic, and we were pleased to have advanced it into Phase 1 clinical testing earlier this month," said Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology. "Issuance of this composition of matter patent is an important development for Kura and the program."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About KO-947
KO-947 is a potent and selective small molecule ERK1/2 inhibitor. KO-947 exhibits potent anti-proliferative activity across a broad panel of tumor cell lines with mutations in BRAF, NRAS or KRAS and demonstrates prolonged pathway inhibition, both in vitro and in vivo. Durable tumor regression has been observed with KO-947 in preclinical cell line and patient derived xenograft models, including KRAS- and BRAF-mutant adenocarcinomas and squamous cell carcinomas lacking BRAF/RAS mutations.